|
Abstract ID |
Neme of the Author |
Abstract Title |
|
1 |
Akanksha Garg |
Experience of Mismatched Unrelated Donor Transplant with PTYC Based GYHD Prophylaxis In Benign Hematological Disorders |
|
3 |
Shweta Pathak |
Establishing a Bone Marrow Transplant Center in a Tier-2 City: Early Experience from a tertiary care government institute in central India |
|
6 |
Priti Sandeep Mehta |
Haploidentical Hematopoeitic Stem Cell transplant (HSCT) –my experience over 2 years in Leukemia,a boon or bane. |
|
7 |
Amitabh Singh |
Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Juvenile Myelomonocytic Leukemia: A Single-Center Experience from a Resource-Limited Setting |
|
8 |
Subhasish Paul |
TCRαβ and CD45RA depleted haploidentical stem cell transplantation for Thalassemia (TDT): Immune reconstitution and viral reactivation. |
|
9 |
Subhasish Paul |
Successful Haplo-identical Hematopoietic Stem Cell Transplantation (HSCT) for Pyruvate Kinase Deficiency (PKD) with TCR αβ and CD45RA Depletion |
|
10 |
Sunisha Arora |
Venetoclax–Azacitidine as A Bridge to Transplant in Pediatric Relapsed/Refractory Acute Myeloid Leukemia: A Real-World Experience |
|
11 |
Parminder Pal Singh |
A Lifeline for Children: The Promise of Allografts in Pediatric Myelodysplastic syndrome – A single center experience from India |
|
12 |
Maharshi Trivedi |
Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Transfusion-Dependent Thalassemia: A Single-Center Experience |
|
13 |
Sohini Chakraborty |
Autologous Stem Cell Rescue in Graft Failures in Patients With Hemoglobinopathies Undergoing Alternate Donor Hematopoietic Stem Cell Transplantation – is it worth it? |
|
15 |
Vikram Yelugoti |
A Case of Post–Allogeneic Stem Cell Transplant Vanishing Bile Duct Syndrome with Complete Recovery |
|
16 |
swati Bhayana |
Half-match, full hope: Success story of haploidentical HSCT in sickle cell disease - a single centre experience from India |
|
17 |
Poornima P |
Title: Single Centre Experience of Allogenic Stem Cell Transplant For Beta Thalassemia Major |
|
18 |
Sunisha Arora |
Comparison Of Busulfan/Cyclophosphamide Versus Treosulfan–Thiotepa–Fludarabine Conditioning Regimens In Matched Donor HSCT For Pediatric Hemoglobinopathies: A Single-Centre Experience |
|
19 |
Swetlana Mukherjee |
Hematopoietic Stem Cell Transplant in a Case of Mucopolysaccharidosis IV with Fanconi Anemia and Bone Marrow Failure |
|
20 |
CHINTAN TARUNKUMAR VYAS |
TCRαβ-Depleted versus Post-Transplant Cyclophosphamide–Based Haploidentical HSCT in Children: A Four-Year Comparative Experience from a Western Indian Tertiary Center |
|
21 |
Chintan Tarunkumar Vyas |
Complete Survival with Alternative Donor HSCT in β-Thalassemia Major: A Single-Center Experience from Western India |
|
22 |
Ruquaiya Alam |
In Vivo T Cell Targeting via Surface-Engineered Lentiviral Vectors with Reduced Off-Target Activity |
|
24 |
Shruti Verma |
Pretransplant Immunosuppression in Hemoglobinopathies – Experience from a tertiary care in North India |
|
25 |
Megadeepan Senthilkumar |
Renal Reserve Guided Conditioning in High Risk Relapsed Wilms Tumour: A Case Supporting Thiotepa–Melphalan as a Renal Sparing Alternative |
|
27 |
Eby P. Baby |
Pre-emptive use of tocilizumab in HSCT: Steroid Sparing Effect. |
|
28 |
Neha Da Rocha |
Predictors of CD34⁺ Yield in Pediatric Stem Cell Harvesting: Experience from a Newly Established Government-Run BMT Centre |
|
29 |
Nikhil Gupta |
Role of Ruxolitinib in HSCT Beyond GvHD |
|
30 |
Vinodh Saravanakumar |
Development of an indigenous cell and gene therapy solution for sickle cell disease and β-thalassemia |
|
31 |
Mohan Ranganathan |
NeoLentiX: An Indigenous Third-Generation Lentiviral Vector Platform for High-Titer, GMP-Compliant Gene Therapy Manufacturing |
|
34 |
Md Shakir |
HYPE-CAR T cells: hypoimmunogenic and persistent allogeneic CAR T cells with CD47/IL-4 inverted cytokine receptor for enhanced immune evasion and durable antitumor response |
|
35 |
Rohini V |
Outcomes of allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia : A single center experience |
|
36 |
Jahnvi Hora |
A Tri-Specific mRNA T-Cell Engager (CD3 × CD19 × CD20) Demonstrates Potent Activity Against B-Cell Leukemia and Lymphoma |
|
38 |
Deeksha Joshi |
ViroVbots: A Targeted In Vivo Lentiviral Gene Therapy Platform for Precision CAR-T Cell Generation in B-Cell Malignancies and Solid Tumors |
|
39 |
Rachit Khandelwal |
Outcomes of CAR T-Cell Therapy in Children with Relapsed B-Cell Acute Lymphoblastic Leukaemia: A Single-Centre Experience |
|
40 |
Rachit Khandelwal |
Acute Neuromuscular Weakness and Myelopathy Following CD19 CAR-T Cell Therapy in a Child with Refractory B-ALL: Disease Progression or Immune-Mediated Neurotoxicity? |
|
42 |
Shantanu Kumar |
De Novo Antibody Discovery Pipeline Through Structure-Aware Generative AI |
|
43 |
Niveditha S Reddy |
Allogenic HSCT in Inherited Bone marrow Failure Syndromes- A Single Center experience |
|
44 |
Neha Rastogi |
Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children with Severe Aplastic Anemia: A Single Centre Experience |
|
47 |
Mugdha Todkar |
Shorter Is Enough? Clinical Outcomes With Early Discontinuation of Antifungal Prophylaxis at Engraftment Post hematopoietic stem cell transplant |
|
48 |
Siddhartha Reddy Dodd |
Clinical Experience With Vedolizumab in Pediatric Acute Graft- Versus-Host Disease: A Single-Center Case Series |
|
49 |
Bindu.C |
Real-world HSCT outcomes in Inherited Bone Marrow Failure Syndromes from a teaching hospital in India: Encouraging outcomes and persistent challenges |
|
50 |
Aparna Ramachandran |
Targeted In Vivo Lentiviral Gene Therapy for Precision CAR-T Cell Generation Against CLDN18.2-Positive Solid Tumors |